Abstract
Prior studies demonstrate that a proteinase fraction from Vasconcellea cundinamarcensis V.M. Badillo, Car-icaceae, exhibits wound healing activity in gastric and cutaneous models and antitumoral/antimetastatic effects. Here, we present the toxicity, pharmacokinetics and biodistribution data for this proteinase fraction following a single dose into Swiss mice by i.v., s.c. or p.o. routes. The i.v. and s.c. toxicity assays demonstrate that proteinase fraction at ⪯20 mg/kg is non-lethal after single injection, while parental administration (p.o.) of ⪯300 mg/kg does not cause death. Based onp.o. acute toxicity dose using Organisation for Economic Cooperation and Development protocols, proteinase fraction ranks as Class IV “harmful” substance. Proteinase fraction shows high uptake determined as Kp (distribution tissue/blood) in organs linked to metabolism and excretion. Also, high bioavailability (≈100%) was observed by s.c. administration. The blood contents following i.v. dose fits into a pharmacokinetic bi-compartmental model, consisting of high removal constants - ke1 0.22 h−1 and kd 2.32 h−1 and a half-life - t1/2 = 3.13 h. The Ames test of proteinase fraction (0.01–1%) demonstrates absence of mutagenic activity. Likewise, genotoxic evaluation of proteinase fraction (5 or 10mg/kg, i.p.) shows no influence in micronuclei frequency. In conclusion, the acute doses for proteinase fraction lack mutagenic and genotoxic activity, clearing the way for clinical assays.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Araujo e Silva, A.C., de Oliveira Lemos, F., Gomes, M.T., Salas, C.E., Lopes, M.T., 2015. Role of gastric acid inhibition, prostaglandins and endogenous-free thiol groups on the gastroprotective effect of a proteolytic fraction from Vasconcellea cundinamarcensis latex. J. Pharm. Pharmacol. 67, 133–141.
Ayello, E.A., Cuddigan, J.E., 2004. Debridement: controlling the necrotic/cellular burden. Adv. Skin Wound Care 17, 66–75.
Baeza, G., Correa, D., Salas, C.E., 1990. Proteolytic enzymes in Carica candamarcensis. J. Sci. FoodAgric. 51, 1–9.
Baumann, A., 2006. Early development of therapeutic biologies - pharmacokinetics. Curr. Drug Metabol. 7, 15–21.
Beuth, J., 2008. Proteolytic enzyme therapy in evidence-based complementary oncology: fact or fiction? Integr. Cancer Ther. 7, 311–316.
Bilheiro, R.P., Braga, A.D., Limborço-Filho, M., Carvalho-Tavares, J., Agero, U., Carvalho, M.G., Sanchez, E.F., Salas, C.E., Lopes, M.T.P., 2013. The thrombolytic action of a proteolytic fraction (P1G10) from Carica candamarcensis. Thromb. Res. 131, 175–182.
Bock, U., Kolac, C., Borchard, G., Koch, It, Fuchs, R., Streichhan, P., Lehr, C.M., 1998. Transport of proteolytic enzymes across Caco-2 cell monolayers. Pharm. Res. 15, 1393–1400.
Boer, A.G., Gaillard, P.J., 2007. Drug targeting to the brain. Annu. Rev. Pharmacol. Toxicol. 47, 323–355.
Brien, S., Lewith, G., Walker, A., Hicks, S.M., Middleton, D., 2004. Bromelain as a treatment for osteoarthritis: a review of clinical studies. Evid. Based Complement Alternat. Med. 1, 251–257.
Castell, J.V., Friedrich, G., Kuhn, C.S., Poppe, G.E., 1997. Intestinal absorption of unde-graded proteins in men: presence of bromelain in plasma after oral intake. Am. J. Physiol. 273, G139–G146.
Coates, G., DeNardo, S.J., DeNardo, G.L., Troy, F., 1974. Pharmacokinetics of radioio-dinated streptokinase. J. Nucl. Med. 16, 136–142.
Dittz, D., Figueiredo, C., Lemos, F.O., Viana, C.T., Andrade, S.P., Souza-Fagundes, E.M., Fujiwara, R.T., Salas, C.E., Lopes, M.T., 2015. Antiangiogenesis, loss of cell adhesion and apoptosis are involved in the antitumoral activity of Proteases from V. cundinamarcensis (C. candamarcensis) in murine melanoma B16F1. Int. J. Mol. Sci. 16, 7027–7044.
Dittz, D., Lopes, M.T.P., Figueiredo, C., Viana, C.T.R., Salas, C.E., 2010. Antitumoral and antimetastatic activities of a proteolytic fraction from Carica candamarcensis latex. Basic Clin. Pharmacol. Toxicol. 107, 162.
Ford, C.N., Reinhard, E.R., Yeh, D., Syrek, D., De Las Morenas, A., Bergman, S.B., Williams, S., Hamori, C.A., 2002. Interim analysis of a prospective, randomized trial of vacuum-assisted closure versus the healthpoint system in the management of pressure ulcers. Ann. Plast. Surg. 49, 55–61.
Gaspani, L., Limiroli, E., Ferrario, P., Bianchi, M., 2002. In vivo and in vitro effects of bromelain on PGE(2) and SP concentrations in the inflammatory exudate in rats. Pharmacology 65, 83–86.
Gibaldi, M., Perrier, D., 1982. Pharmacokinetics. Marcel Dekker, Inc., New York.
Goldberg, M., Gomez-Orellana, I., 2003. Challenges for the oral delivery of macro-molecules. Nat. Rev. Drug Discov. 2, 289–295.
Gomes, F.S., Spínola, C.V., Ribeiro, H.A., Lopes, M.T., Cassali, G.D., Salas, C.E., 2010. Wound-healing activity of a proteolytic fraction from Carica candamarcensis on experimentally induced burn. Burns 36, 277–283.
Gomes, M.T., Oliva, M.X., Lopes, M.T.P., Salas, C.E., 2011. Plant proteinases and inhibitors: an overview of biological function and pharmacological activity. Curr. Protein Pept. Sci. 12, 417–436.
Gooiden, A.W., Glass, H.I., Williams, E.D., 1971. Use of 99mTc forthe routine assessment of thyroid function. Br. Med. J. 13, 396–399.
Grabovac, V., Schmitz, T., Föger, F., Bernkop-Schnürch, A., 2007. Papain: an effective permeation enhancer for orally administered low molecular weight heparin. Pharm. Res. 24, 1001–1006.
Kolac, C., Streichhan, P., Lehr, C.M., 1996. Oral bioavailability of proteolytic enzymes. Eur. J. Biopharm. 42, 222–232.
Komarek, P., Kleisner, I., Komarkova, I., Konopkova, M., 2005. Accumulation of radi-olabelled low molecular peptides and proteins in experimental inflammation. Int.J. Pharm. 291, 119–125.
Lemos, F.O., Ferreira, L.A., Cardoso, V.N., Cassali, G.D., Salas, C.E., Lopes, M.T., 2011. Skin-healing activity and toxicological evaluation of a proteinase fraction from Carica candamarcensis. Eur. J. Dermatol. 21, 722–730.
Lima-Filho, J.V., Patriota, J.M., Silva, A.F., Filho, N.T., Oliveira, R.S., Alencar, N.M., Ramos, M.V., 2010. Proteins from latex of Calotropis procera prevent septic shock due to lethal infection by Salmonella enteric serovar Typhimurium. J. Ethnopharmacol. 129, 327–334.
Mahmood, I., Green, M.D., 2005. Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins. Clin. Pharmacokinet 44, 331–347.
Maron, D.M., Ames, B.N., 1983. Revised methods for the Salmonella mutagenicity test. Mutation Res. 113, 173–215.
Melano, E., Rodriguez, H.L., Carrillojr, R., Dillon, L., 2004. The effects of Panafil when using topical negative pressure to heal an infected sternal wound. J. Wound Care 13, 425–426.
Mello, V.J., Gomes, M.T., Lemos, F.O., Delfíno, J.L., Andrade, S.P., Lopes, M.T., Salas, C.E., 2008. The gastric ulcer protective and healing role of cysteine proteinases from Carica candamarcensis. Phytomedicine 15, 237–244.
Mello, V.J., Gomes, M.T.R., Rodrigues, K.C.L., Sanchez, E.F., Lopes, M.T.P., Salas, C.E., 2006. Plant proteinases: their potential as therapeutic drugs. In: Govil, J.N., Singh, V.K., Arunachalam, C. (Eds.), Drug Development from Molecules. Studium Press, Texas, pp. 211–224.
Mortelmans, It, Zeiger, E., 2000. The Ames Salmonella/microsome mutagenicity assay. Mutation Res. 455, 29–60.
Moss, I.N., Frazier, C.V., Martin, G.J., 1963. Bromelain - the pharmacology of the enzyme. Arch. Int. Pharmacodyn 145, 166–189.
Nunan, E.A., Cardoso, V.N., Moraes-Santos, T., 2002. Technetium-99m labeling of tityustoxin and venom from the scorpion Tityus serrulatus. Appl. Radiat. Isot. 57, 849–852.
OECD, 2001. Acute Oral Toxicity: Fixed Dose Procedure - Guideline for Testing of Chemicals N. 420. Organisation for Economic Cooperation and Development, Paris.
Pariza, M.W., Johnson, E.A., 2001. Evaluating the safety of microbial enzyme preparations used in food processing: update for a new century. Regul. Toxicol. Pharmacol. 33, 173–186.
Som, P., Rhodes, B.A., Bell, W.R., 1975. Radiolabeled streptokinase and urokinase and their comparative biodistribution. Thromb. Res. 6, 247–253.
Tang, L., Persky, A.M., Hochhaus, G., Meibohm, B., 2004. Pharmacokinetic aspects of biotechnology products. J. Pharm. Sci. 93, 2184–2204.
Taussig, S.J., Yokoyama, M.M., Chinenn, E.T., 1975. Bromelain: a proteolytic enzyme and its clinical application. Hiroshima J. Med. Sci. 24, 185–193.
Teixeira, R.D., Ribeiro, H.A., Gomes, M.T., Lopes, M.T., Salas, C.E., 2008. The proteolytic activities in latex from Carica candamarcensis. Plant Physiol. Biochem. 46, 956–961.
Toon, S., 1996. The relevance of pharmacokinetics in the development of biotechnology products. Eur. J. Drug Metab. Pharmacokinet 21, 93–103.
USP 24, 2000. The National Formulary - NF 19. United States Pharmacopeia Convention, Rockville.
USP 34, 2011. The National Formulary - NF 29. United States Pharmacopeia Convention, Rockville.
Wald, M., 2008. Exogenous proteases confer a significant chemopreventive effect in experimental tumor models. Integr. CancerTher. 7, 295–310.
Wasan, K.M., 2002. The role of lymphatic transport in enhancing oral protein and peptide drug delivery. Drug Dev. Ind. Pharm. 28, 1047–1058.
Acknowledgments
We would like to thank Luciana M Siqueira for technical and CNPq, CAPES and FAPEMIG for financial support.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
The authors declare no conflicts of interest.
Rights and permissions
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Lemos, F.O., Villalba, M.I.C., Tagliati, C.A. et al. Biodistribution, pharmacokinetics and toxicity of a Vasconcellea cundinamarcensis proteinase fraction with pharmacological activity. Rev. Bras. Farmacogn. 26, 94–101 (2016). https://doi.org/10.1016/j.bjp.2015.09.008
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1016/j.bjp.2015.09.008